SCHEMBL6488896

SCHEMBL6488896

CCOC(=O)c1cc(C)c2nc(C)n(Cc3ccc(OCC)cc3Cl)c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 5/20 0.40
PPARG P37231 1/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 7/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
GAA P10253 2/20 0.37
NPC1 O15118 2/20 0.36
MEN1 O00255 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
USP2 O75604 1/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489090 0.92 PPARG (0.43) DCTPP1PPARGLMNASMN1; SMN2TDP1
SCHEMBL6489130 0.90 MAPT (0.40) DCTPP1PPARGLMNASMN1; SMN2MAPT
SCHEMBL6488419 0.89 LMNA (0.49) DCTPP1PPARGLMNASMN1; SMN2MAPT
SCHEMBL6487673 0.87 JMJD6 (0.41) DCTPP1LMNASMN1; SMN2MAPTTP53
SCHEMBL7657817 0.85 PPARG (0.51) DCTPP1PPARGSMN1; SMN2MAPTALDH1A1
SCHEMBL6503273 0.85 CYP1A2 (0.42) PPARGLMNASMN1; SMN2MAPTALDH1A1
SCHEMBL6489511 0.83 PPARG (0.39) DCTPP1PPARGLMNASMN1; SMN2NPSR1
SCHEMBL6490611 0.83 ERN1 (0.37) DCTPP1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL6490742 0.83 CYP1A2 (0.38) DCTPP1LMNASMN1; SMN2MAPTALDH1A1
SCHEMBL6488456 0.83 DCTPP1 (0.44) DCTPP1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD DCTPP1 1534/4885PPARG 233/4885LMNA 3711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.